Drugs and vascular dementia.
Between 20 and 35% of all dementias are vascular in origin, their etiology is due to cerebrovascular disease and the risk factors are known (e.g. hypertension, diabetes, smoking, or hyperlipidemia). Primary and secondary preventions are the basis of therapeutics. Symptomatic treatment is emerging, notably in the field of cognitive disorders. In that respect, monoamine oxidase inhibitors, and more recently acetylcholinesterase inhibitors, are in the process of being recognized as first-line treatments of established vascular dementia.
Allain
Hervé
H
Laboratory of Pharmacology, Faculty of Medicine, University of Rennes I, 2 avenue du Pr. Leon Bernard, CS 34317, F-35043 Rennes cedex, France. Harve.Allain@univ-rennes1.fr
Bentue-Ferrer
Danièle
D
Tribut
Olivier
O
Pinel
Jean-François
JF
D000368:Aged; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D015140:Dementia, Vascular / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use*
D002800:Cholinesterase Inhibitors; D018696:Neuroprotective Agents